Jérôme Desrame

3.6k citations

106 papers · 1.4k indexed · 1 hit paper · h-index 20

Impact in

Oncology top 5%
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
Gastroenterology top 5%

Papers in ⓘ

Oncology 48
- Colorectal Cancer Treatments and Studies 24
- Pancreatic and Hepatic Oncology Research 20
- Cancer Treatment and Pharmacology 11
Gastroenterology 8

Co-authors: Dominique Béchade (39 shared papers)Christophe Louvet (18 shared papers)Thierry André (17 shared papers)Thomas Aparicio (14 shared papers)David Tougeron (12 shared papers)Julien Taı̈eb (23 shared papers)Christophe Tournigand (7 shared papers)C Duvic (5 shared papers)
Journals: Journal of Clinical Oncology (20 papers)Annals of Oncology (12 papers)The American Journal of Gastroenterology (2 papers)Digestive and Liver Disease (2 papers)Cancer (1 paper)
Partner nations: France Switzerland Italy

In The Last Decade

Jérôme Desrame

93 papers receiving 1.4k citations

Hit Papers

align trajectories log scale

Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study 2022 · 220 citations

Peers

Countries citing papers authored by Jérôme Desrame

Since Specialization

Citations

This map shows the geographic impact of Jérôme Desrame's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jérôme Desrame with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jérôme Desrame more than expected).

Fields of papers citing papers by Jérôme Desrame

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jérôme Desrame. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jérôme Desrame. The network helps show where Jérôme Desrame may publish in the future.

Co-authors

The 25 scholars most cited alongside Jérôme Desrame, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jérôme Desrame Line = papers co-authored together Jérôme Desrame links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 106 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instability–High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study Journal of Clinical Oncology ·Thierry André, David Tougeron, Guillaume Piessen, Christelle de la Fouchardière, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jérôme Desrame, Astrid Lièvre, Marie‐Line Garcia‐Larnicol, T. Pudlarz, Romain Cohen, Salomé Memmi, Dewi Vernerey, Julie Henriques, Jérémie H. Lefèvre, Magali Svrcek Hit paper breakdown →	2022	220
2	Second‐line chemotherapy for advanced biliary tract cancer after failure of the gemcitabine‐platinum combination: A large multicenter study by the Association des Gastro‐Entérologues Oncologues Cancer ·Bertrand Brieau, Laëtitia Dahan, Yann De Rycke, Tarek Boussaha, Philippe Vasseur, David Tougeron, Thierry Lecomte, Romain Coriat, Jean‐Baptiste Bachet, Pierre Claudez, Aziz Zaanan, Pauline Soibinet, Jérôme Desrame, Anne Thirot‐Bidault, Isabelle Trouilloud, Florence Mary, Lysiane Marthey, Julien Taı̈eb, Wulfran Cacheux, Astrid Lièvre	2015	95
3	Modified FOLFIRINOX Versus CISGEM Chemotherapy for Patients With Advanced Biliary Tract Cancer (PRODIGE 38 AMEBICA): A Randomized Phase II Study Journal of Clinical Oncology ·Jean–Marc Phelip, Jérôme Desrame, Julien Edeline, Emilie Barbier, Eric Terrebonne, Pierre Michel, Hervé Perrier, Laëtitia Dahan, V. Bourgeois, F. Khemissa Akouz, Émilie Soularue, Valérie Lebrun Ly, Yann Molin, Thierry Lecomte, François Ghiringhelli, Romain Coriat, Samy Louafi, Cindy Neuzillet, Sylvain Manfrédi, David Malka, (unknown)	2021	79
4	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: a Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial Clinical Cancer Research ·Julien Taı̈eb, Valérie Taly, Julie Henriques, Camille Bourreau, Laurent Mineur, Jaafar Bennouna, Jérôme Desrame, Christophe Louvet, Céline Lepère, May Mabro, Joëlle Egreteau, Olivier Bouché, Claire Mulot, Katia Hormigos, Kariman Chaba, Thibault Mazard, Aimery de Gramont, Déwi Vernerey, Thierry André, Pierre Laurent‐Puig	2021	71
5	Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study The Oncologist ·Benoist Chibaudel, Franck Bonnetain, Christophe Tournigand, Leïla Bengrine-Lefèvre, Luís Teixeira, Pascal Artru, Jérôme Desrame, Annette K. Larsen, Thierry André, Christophe Louvet, Aimery de Gramont	2011	57
6	Retroperitoneal fibrosis, sclerosing pancreatitis and bronchiolitis obliterans with organizing pneumonia Nephrology Dialysis Transplantation ·C Duvic, Jérôme Desrame, Christophe Lévêque, G Nédélec	2004	54
7	Outbreak of enterically-transmitted hepatitis due to hepatitis A and hepatitis E viruses Journal of Hepatology ·Pierre Coursaget, Yves Buisson, Nathalie Enogat, Raymond Bercion, Jean-Marie Baudet, Patrick Delmaire, Dominique Prigent, Jérôme Desrame	1998	49
8	Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration Annals of Oncology ·Julien Taı̈eb, Valérie Taly, Déwi Vernerey, Camille Bourreau, Jaafar Bennouna, Roger Faroux, Jérôme Desrame, Olivier Bouché, Christophe Borg, Joëlle Egreteau, Laurent Mineur, Céline Lepère, G. Deplanque, Claire Mulot, Christophe Louvet, May Mabro, Marc Ychou, Aimery de Gramont, Thierry André, Pierre Laurent‐Puig	2019	47
9	Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial Journal of Clinical Oncology ·Laëtitia Dahan, Nicolas Williet, Karine Le Malicot, Jean–Marc Phelip, Jérôme Desrame, Olivier Bouché, Caroline Pétorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne-Laure Bignon, Jean‐Baptiste Bachet, Jean‐François Seitz, Côme Lepage, Éric François, (unknown)	2021	45
10	Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in patients (pts) with localized microsatellite instability-high (MSI)/mismatch repair deficient (dMMR) oeso-gastric adenocarcinoma (OGA): The GERCOR NEONIPIGA phase II study. Journal of Clinical Oncology ·Thierry André, David Tougeron, Guillaume Piessen, Christelle de la Fouchardière, Christophe Louvet, Antoine Adenis, Marine Jary, Christophe Tournigand, Thomas Aparicio, Jérôme Desrame, Astrid Lièvre, Marie‐Line Garcia‐Larnicol, T. Pudlarz, Julie Henriques, Romain Cohen, Jérémie H. Lefèvre, Magali Svrcek	2022	42
11	FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid and irinotecan, for advanced pancreatic cancer: results of an Association des Gastro-Entérologues Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study Annals of Oncology ·Julien Taı̈eb, Thierry Lecomte, Thomas Aparicio, Amani Asnacios, Touraj Mansourbakht, Pascal Artru, David Fallik, Jean‐Philippe Spano, B. Landi, Gérard Lledo, Jérôme Desrame	2006	40
12	Folfirinox versus gemcitabine/nab-paclitaxel as first-line therapy in patients with metastatic pancreatic cancer: a comparative propensity score study Therapeutic Advances in Gastroenterology ·Nicolas Williet, Angélique Saint, Anne‐Laure Pointet, David Tougeron, Simon Pernot, Astrid Pozet, Dominique Béchade, Isabelle Trouilloud, Nelson Lourenço, Vincent Hautefeuille, Christophe Locher, Jérôme Desrame, Pascal Artru, Anne Thirot Bidault, Bertrand Le Roy, Denis Pezet, Jean–Marc Phelip, Julien Taı̈eb	2019	40
13	Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: Study protocol for a randomized controlled multicenter phase II/III study Digestive and Liver Disease ·Jean-Marc Phelip, Julien Edeline, Jean‐Frédéric Blanc, Emilie Barbier, Pierre Michel, V. Bourgeois, Cindy Neuzillet, David Malka, Sylvain Manfrédi, Jérôme Desrame	2018	37
14	FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX). Journal of Clinical Oncology ·Laëtitia Dahan, Jean–Marc Phelip, Karine Le Malicot, Nicolas Williet, Jérôme Desrame, Julien Volet, Caroline Pétorin, David Malka, Christine Rebischung, Thomas Aparicio, Cédric Lecaille, Yves Rinaldi, Anthony Turpin, Anne Bignon, Jean‐Baptiste Bachet, Jean François Seitz, Côme Lepage, Éric François	2018	37
15	Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial The Lancet. Gastroenterology & hepatology ·Jean‐Baptiste Bachet, Pascal Hammel, Jérôme Desrame, Aurélia Meurisse, Benoist Chibaudel, Thierry André, P. Debourdeau, Jérôme Dauba, Thierry Lecomte, Jean‐François Seitz, Christophe Tournigand, Thomas Aparicio, Véronique Guérin Meyer, Julien Taı̈eb, Julien Volet, Amandine Monier, Franck Bonnetain, Christophe Louvet	2017	26
16	Gastritis cystica profunda in a patient with no history of gastric surgery Endoscopy ·Dominique Béchade, Jérôme Desrame, J.-P. Algayrès	2007	23
17	Hyponatrémie due au tramadol La Revue de Médecine Interne ·J-P Le Berre, Jérôme Desrame, S. Lecoules, G Coutant, Dominique Béchade, J.-P. Algayrès	2007	21
18	FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients PLoS ONE ·Cindy Serdjebi, Johan Gagnière, Jérôme Desrame, Francine Fein, Rosine Guimbaud, E. François, Thierry André, Jean‐François Seitz, Carole Montérymard, Dominique Arsène, Julien Volet, Abakar Abakar-Mahamat, Thierry Lecomte, Véronique Guerin‐Meyer, Jean-Louis Legoux, G. Deplanque, Pierre Guillet, Joseph Ciccolini, Côme Lepage, Laëtitia Dahan	2015	20
19	Assessment of Hypothalamic-Pituitary-Adrenal Axis Function After Corticosteroid Therapy in Inflammatory Bowel Disease The American Journal of Gastroenterology ·Jérôme Desrame, J M Sabaté, Rachid Agher, C Brémont, M Gaudric, Daniel Couturier, Stanislas Chaussade	2002	19
20	LBA41 Nivolumab (nivo) ± ipilimumab (ipi) in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) (GCO-001 NIPINEC) Annals of Oncology ·Nicolas Girard, Julien Mazières, Josiane Otto, H. Léna, C. Lepage, Thomas Egenod, Denis Smith, J. Madelaine, L. Gérinière, Farid El Hajbi, Aurélie Ferru, Christelle Clément-Duchêne, Anne Madroszyk, Jérôme Desrame, Franck Morin, Alexandra Langlais, Pierre Michel, Christophe Louvet, Virginie Westeel, Thomas Walter	2021	19

About Jérôme Desrame

Jérôme Desrame is a scholar working on Oncology, Gastroenterology, Hepatology, Pulmonary and Respiratory Medicine and Surgery, having authored 106 papers that have together received 1.4k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (24 papers), Pancreatic and Hepatic Oncology Research (20 papers), Cancer Genomics and Diagnostics (12 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (12 papers), Cancer Treatment and Pharmacology (11 papers), Gastric Cancer Management and Outcomes (11 papers), Gastrointestinal disorders and treatments (9 papers) and Genetic factors in colorectal cancer (8 papers). The work is most often cited by research in Oncology (762 citations), Gastroenterology (129 citations), Pulmonary and Respiratory Medicine (596 citations), Cancer Research (250 citations) and Hepatology (119 citations). Jérôme Desrame has collaborated with scholars based in France, Switzerland and Italy. Frequent co-authors include Dominique Béchade, Christophe Louvet, Thierry André, Thomas Aparicio, David Tougeron, Julien Taı̈eb, Christophe Tournigand, C Duvic, Julie Henriques and Astrid Lièvre. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, The American Journal of Gastroenterology, Digestive and Liver Disease and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact